Array BioPharma Case: Delhi High Court Pharma Patent Ruling

Explore the Delhi High Court's landmark Array BioPharma judgment. Discover key insights on drug combination patents, Section 3(d), and Section 3(i) in India. 

The Delhi High Court’s decision in Array BioPharma Inc. v. Deputy Controller of Patents and Designs (C.A.(COMM.IPD-PAT) 37/2023) is a watershed moment for pharmaceutical patent prosecution in India. Presided over by Justice Tushar Rao Gedela, this ruling provides vital legal clarity on multi-component pharmaceutical inventions, cancer drug combinations, and the boundaries of patentability under the Indian Patents Act, 1970.

If you are navigating patent strategy, biotechnology IP, or life sciences law in India, understanding this Delhi High Court patent judgment is essential.

Case Background & Summary

Array BioPharma sought a patent for a specialized triple-drug pharmaceutical combination targeting proliferative diseases like cancer. The combination comprised:

-Encorafenib (a B-Raf inhibitor)

-Cetuximab or Erlotinib (EGFR inhibitors)

-Alpelisib (an optional PI3K-alpha inhibitor)

The Indian Patent Office (IPO) initially rejected the application, citing a lack of inventive step under Section 2(1)(ja), non-patentability under Section 3(d) (as a derivative of known substances), and exclusion under Section 3(i) (as a method of treatment).

The Delhi High Court set aside the Controller’s refusal order entirely, remanding the patent application for de novo (fresh) consideration.

Key Legal Takeaways for Patent Practitioners

1. Product Claims vs. Methods of Treatment (Section 3(i))

A frequent roadblock for pharma innovators in India is the IPO misinterpreting product claims that mention administration routes. The Controller argued that phrasing like "for simultaneous, separate or sequential administration" and clinical trial references turned the patent into a medical protocol.

The Court's Ruling: Reaffirming precedents like Bayer Pharma, the Court held that working examples and administration schedules merely establish practical utility and workability. Because the claims were framed as physical combination products rather than a medical process, Section 3(i) does not apply.

2. The Inapplicability of Section 3(d) to Independent Actives

Section 3(d) bars the patenting of mere discoveries or new forms of known substances unless they demonstrate enhanced efficacy.

The Court's Ruling: The Court reiterated that Section 3(d) does not capture combinations of distinct, independently active pharmaceutical agents. The IPO committed a fundamental error by failing to identify the specific "known compound" from which the claimed combination was allegedly derived.

3. Striking Down Hindsight Bias in Inventive Step (Section 2(1)(ja))

The IPO had patched together elements from four disparate prior art documents (D1 to D4) to argue obviousness.

The Court's Ruling: The judgment strongly rebukes "hindsight analysis." The Patent Office must articulate an explicit motivation for a Person Skilled in the Art (PSITA) to combine specific teachings with a reasonable expectation of success, rather than cherry-picking isolated components. Furthermore, empirical clinical trial data showing profound tumor regression must be genuinely evaluated as evidence of technical advancement.

Why This Judgment Matters for Life Sciences Innovators

This Delhi High Court ruling acts as a strong protective shield for pharmaceutical companies investing in targeted combination therapies and anti-cancer drug regimens. It reinforces that well-drafted product claims backed by solid clinical data can successfully overcome rigid regulatory hurdles in the Indian patent system.